-
1.发明申请Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists 审中-公开杂芳基咪唑衍生物作为大麻素CB1受体拮抗剂公开(公告)号：US20080207705A1
公开(公告)日：2008-08-28
申请号：US12037986
申请日：2008-02-27
申请人： Jinhwa LEE , Jeongmin Kim , Jong Yup Kim , Hee Jeong Seo , Myung Eun Jung , Sung-Han Lee , Kwangwoo Ahn , Suk Ho Lee
发明人： Jinhwa LEE , Jeongmin Kim , Jong Yup Kim , Hee Jeong Seo , Myung Eun Jung , Sung-Han Lee , Kwangwoo Ahn , Suk Ho Lee
IPC分类号： A61K31/4245 , C07D413/04 , A61K31/433 , A61K31/426 , A61P3/04 , A61K31/421 , C07D417/04
CPC分类号： C07D417/04 , C07D413/04 , C07D413/14 , C07D417/14
摘要： A novel heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
摘要翻译： 式（I）的新型杂芳基 - 咪唑化合物或其药学上可接受的盐作为大麻素CB 1受体反向激动剂或拮抗剂是有效的，其可用于预防或治疗肥胖症和肥胖相关代谢 疾病 本发明还提供其制备方法，含有该组合物的药物组合物，以及预防或治疗肥胖症和与肥胖有关的代谢紊乱的方法。
-
2.发明申请HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS 审中-公开作为CANNABINOID CB1受体拮抗剂的异氟醚咪唑衍生物公开(公告)号：US20080207704A1
公开(公告)日：2008-08-28
申请号：US11679742
申请日：2007-02-27
申请人： Jinhwa Lee , Jeongmin Kim , Jong Yup Kim , Hee Jeong Seo , Myung Eun Jung , Sung-Han Lee , Kwangwoo Ahn
发明人： Jinhwa Lee , Jeongmin Kim , Jong Yup Kim , Hee Jeong Seo , Myung Eun Jung , Sung-Han Lee , Kwangwoo Ahn
IPC分类号： A61K31/41 , A61K31/422 , A61K31/4245 , A61K31/427 , C07D413/04 , C07D417/04
CPC分类号： C07D417/04 , C07D413/04
摘要： A heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing a heteroaryl-imidazole compound of formula (I), a pharmaceutical composition containing a heteroaryl-imidazole compound of formula (I), and a method for preventing or treating obesity and obesity-related metabolic disorders.
摘要翻译： 式（I）的杂芳基 - 咪唑化合物或其药学上可接受的盐作为大麻素CB 1受体反向激动剂或拮抗剂是有效的，其可用于预防或治疗肥胖症和与肥胖相关的代谢紊乱 。 本发明还提供了制备式（I）的杂芳基 - 咪唑化合物的方法，含有式（I）的杂芳基 - 咪唑化合物的药物组合物，以及预防或治疗肥胖症和与肥胖有关的代谢紊乱的方法。
-
公开(公告)号：US20080262066A1
公开(公告)日：2008-10-23
申请号：US12105460
申请日：2008-04-18
申请人： Jinhwa LEE , Jeongmin Kim , Kwang-Seop Song , Min Ah Kim , Jong Yup Kim , Suk Ho Lee , Hee Jeong Seo , Sung-Han Lee , Myung Eun Jung , Kwang Woo Ahn , Eun Jung Son
发明人： Jinhwa LEE , Jeongmin Kim , Kwang-Seop Song , Min Ah Kim , Jong Yup Kim , Suk Ho Lee , Hee Jeong Seo , Sung-Han Lee , Myung Eun Jung , Kwang Woo Ahn , Eun Jung Son
IPC分类号： A61K31/415 , C07D231/14 , A61K31/4164 , A61P3/00 , C07D233/54
CPC分类号： C07D231/14 , C07D233/90
摘要： A novel azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
摘要翻译： 式（I）的新型唑化合物或其药学上可接受的盐作为大麻素CB 1受体反向激动剂或拮抗剂是有效的，其可用于预防或治疗肥胖症和与肥胖有关的代谢紊乱。 预防还提供其制备方法，含有其的药物组合物，以及预防或治疗肥胖症和肥胖相关的代谢紊乱的方法。
-
4.发明申请NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 有权新颖的含有阿维菌素的咪唑烷四羧酰胺衍生物和包含其的药物组合物公开(公告)号：US20120115881A1
公开(公告)日：2012-05-10
申请号：US13383143
申请日：2010-07-09
申请人： Jinhwa Lee , Hee Jeong Seo , Suk Youn Kang , Eun-Jung Park , Min Ju Kim , Suk Ho Lee , Jong yup Kim , Jeongmin Kim , Myung Eun Jung , Hyun Jung Kim , Mi-soon Kim , Ho kyun Han , Kwang Woo Ahn , Min Woo Lee , Ki-Nam Lee , Ae Nim Pae , Woo-Kyu Park
发明人： Jinhwa Lee , Hee Jeong Seo , Suk Youn Kang , Eun-Jung Park , Min Ju Kim , Suk Ho Lee , Jong yup Kim , Jeongmin Kim , Myung Eun Jung , Hyun Jung Kim , Mi-soon Kim , Ho kyun Han , Kwang Woo Ahn , Min Woo Lee , Ki-Nam Lee , Ae Nim Pae , Woo-Kyu Park
IPC分类号： A61K31/497 , A61P25/24 , C07D403/12
CPC分类号： C07D417/14 , A61K31/496 , C07D233/88 , C07D401/12 , C07D403/06 , C07D405/04
摘要： A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.
摘要翻译： 提供了一种新的含有芳基哌嗪的咪唑-4-甲酰胺衍生物或其药学上可接受的盐，以及包含其作为预防或治疗抑郁障碍的活性成分的药物组合物。
-
5.发明授权Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same 有权含有芳基哌嗪的咪唑4-甲酰胺衍生物和包含其的药物组合物公开(公告)号：US08835436B2
公开(公告)日：2014-09-16
申请号：US13383143
申请日：2010-07-09
申请人： Jinhwa Lee , Hee Jeong Seo , Suk Youn Kang , Eun-Jung Park , Min Ju Kim , Suk Ho Lee , Jong Yup Kim , Jeongmin Kim , Myung Eun Jung , Hyun Jung Kim , Mi-soon Kim , Ho Kyun Han , Kwang Woo Ahn , Min Woo Lee , Ki-Nam Lee , Ae Nim Pae , Woo-Kyu Park
发明人： Jinhwa Lee , Hee Jeong Seo , Suk Youn Kang , Eun-Jung Park , Min Ju Kim , Suk Ho Lee , Jong Yup Kim , Jeongmin Kim , Myung Eun Jung , Hyun Jung Kim , Mi-soon Kim , Ho Kyun Han , Kwang Woo Ahn , Min Woo Lee , Ki-Nam Lee , Ae Nim Pae , Woo-Kyu Park
IPC分类号： A61K31/496 , C07D233/88 , C07D401/12 , C07D403/06 , C07D405/04 , C07D417/14
CPC分类号： C07D417/14 , A61K31/496 , C07D233/88 , C07D401/12 , C07D403/06 , C07D405/04
摘要： A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.
摘要翻译： 提供了一种新的含有芳基哌嗪的咪唑-4-甲酰胺衍生物或其药学上可接受的盐，以及包含其作为预防或治疗抑郁障碍的活性成分的药物组合物。
-
6.发明授权Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same 有权作为SGLT2抑制剂的噻唑衍生物和包含其的药物组合物公开(公告)号：US08586550B2
公开(公告)日：2013-11-19
申请号：US13704081
申请日：2011-06-10
申请人： Jinhwa Lee , Jeongmin Kim , Suk Ho Lee , Junwon Lee , Kwang-Seop Song , Eun-Jung Park , Min Ju Kim , Hee Jeong Seo , Sung-Han Lee , Eun Jung Son , Jong Yup Kim , Suk Youn Kang , Younggyu Kong
发明人： Jinhwa Lee , Jeongmin Kim , Suk Ho Lee , Junwon Lee , Kwang-Seop Song , Eun-Jung Park , Min Ju Kim , Hee Jeong Seo , Sung-Han Lee , Eun Jung Son , Jong Yup Kim , Suk Youn Kang , Younggyu Kong
IPC分类号： A61K31/70 , A61K31/425 , C07H5/04 , C07H5/06 , C07D277/60
CPC分类号： C07H7/04 , C07D309/10 , C07D417/10 , C07D417/14 , C07D493/10 , C07H17/02
摘要： The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
摘要翻译： 本发明涉及一种具有对存在于肠和肾中的钠依赖性葡萄糖协同转运蛋白2（SGLT2）具有抑制活性的噻唑环的新型化合物，以及包含其作为活性成分的药物组合物，其可用于预防 或治疗代谢紊乱，特别是糖尿病。
-
7.发明申请Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same 有权噻唑衍生物作为SGLT2抑制剂和药物组合物组成公开(公告)号：US20130090298A1
公开(公告)日：2013-04-11
申请号：US13704081
申请日：2011-06-10
申请人： Jinhwa Lee , Jeongmin Kim , Suk Ho Lee , Junwon Lee , Kwang-Seop Song , Eun-Jung Park , Min Ju Kim , Hee Jeong Seo , Sung-Han Lee , Eun Jung Son , Jong Yup Kim , Suk Youn Kang , Younggyu Kong
发明人： Jinhwa Lee , Jeongmin Kim , Suk Ho Lee , Junwon Lee , Kwang-Seop Song , Eun-Jung Park , Min Ju Kim , Hee Jeong Seo , Sung-Han Lee , Eun Jung Son , Jong Yup Kim , Suk Youn Kang , Younggyu Kong
CPC分类号： C07H7/04 , C07D309/10 , C07D417/10 , C07D417/14 , C07D493/10 , C07H17/02
摘要： The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
摘要翻译： 本发明涉及一种具有对存在于肠和肾中的钠依赖性葡萄糖协同转运蛋白2（SGLT2）具有抑制活性的噻唑环的新型化合物，以及包含其作为活性成分的药物组合物，其可用于预防 或治疗代谢紊乱，特别是糖尿病。
-
8.发明授权C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same 有权C-芳基葡糖苷SGLT2抑制剂和包含其的药物组合物公开(公告)号：US08541380B2
公开(公告)日：2013-09-24
申请号：US13379301
申请日：2010-06-18
申请人： Jinhwa Lee , Suk Ho Lee , Hee Jeong Seo , Min Ju Kim , Suk Youn Kang , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Eun Jung Son , Kwang-Seop Song , Mi-Soon Kim
发明人： Jinhwa Lee , Suk Ho Lee , Hee Jeong Seo , Min Ju Kim , Suk Youn Kang , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Eun Jung Son , Kwang-Seop Song , Mi-Soon Kim
CPC分类号： C07D417/14 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/10
摘要： A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.
摘要翻译： 在肠和肾中存在对钠依赖性葡萄糖共转运体2（SGLT2）具有抑制活性的新型C-芳基葡糖苷化合物或其药学上可接受的盐或前药; 并且提供了包含其作为活性成分的药物组合物，其可用于预防或治疗代谢紊乱，特别是糖尿病。
-
9.发明申请NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME 有权新型C-ARYL GLUCOSIDE SGLT2抑制剂和包含其的药物组合物公开(公告)号：US20120101051A1
公开(公告)日：2012-04-26
申请号：US13379301
申请日：2010-06-18
申请人： Jinhwa Lee , Suk Ho Lee , Hee Jeong Seo , Min Ju Kim , Suk Youn Kang , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Eun Jung Son , Kwang-Seop Song , Mi-Soon Kim
发明人： Jinhwa Lee , Suk Ho Lee , Hee Jeong Seo , Min Ju Kim , Suk Youn Kang , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Eun Jung Son , Kwang-Seop Song , Mi-Soon Kim
IPC分类号： A61K31/706 , A61P3/10 , A61P3/00 , C08B37/00 , A61K31/7056
CPC分类号： C07D417/14 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/10
摘要： A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.
摘要翻译： 在肠和肾中存在对钠依赖性葡萄糖共转运体2（SGLT2）具有抑制活性的新型C-芳基葡糖苷化合物或其药学上可接受的盐或前药; 并且提供了包含其作为活性成分的药物组合物，其可用于预防或治疗代谢紊乱，特别是糖尿病。
-
10.发明申请ORALLY BIOAVAILABLE PRODUCTS OF (+)-3-HYDROXYMORPHINAN FOR PARKINSON'S DISEASE PREVENTION OR TREATMENT 失效（+） - 3-羟基吗啡酮用于帕金森病防治或治疗的ORALLY BIOAVAILABLE产品公开(公告)号：US20100113500A1
公开(公告)日：2010-05-06
申请号：US12530444
申请日：2008-03-07
申请人： Jinhwa Lee , Jeongmin Kim , Myung Eun Jung , Jong Yup Kim , Kwang-Seop Song , Eun Jung Son , Suk Ho Lee , Ho Kyun Han , Min Ju Kim , MinWoo Lee
发明人： Jinhwa Lee , Jeongmin Kim , Myung Eun Jung , Jong Yup Kim , Kwang-Seop Song , Eun Jung Son , Suk Ho Lee , Ho Kyun Han , Min Ju Kim , MinWoo Lee
IPC分类号： A61K31/4748 , C07D221/28 , A61P25/16
CPC分类号： C07D221/28
摘要： The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease.
摘要翻译： 本发明涉及式（I）的（+） - 3-羟基吗啡喃化合物或其药学上可接受的盐，其制备方法及其用于预防或治疗帕金森病的新型前药。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.043 秒)
